Rebate Game Played By PBMs And Drug Makers Limits Biosimilar Competition
The rebate game played by drug makers and pharmacy benefit managers limits optimal biosimilar competition. As a result, U.S.
With $66 million R&D center, Boehringer Ingelheim fulfills economic development pledge to state
The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...
Altimmune says pemvidutide given ‘clean safety bill of health’ by FDA
At the Guggenheim Securities Healthcare Innovation Conference, Altimunne said earlier: “So the first thing is that survodutide has a ...
‘Sick day’ on the clock: CT Biopharma firm expands patient simulations to spark creativity, empathy
Spending the day facing the challenges of kidney patients helps workers at a CT pharmaceutical company understand disease and ...
FierceBiotech11d
Boehringer Ingelheim drops obesity drug from Gubra partnership
Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, ...
German pharmaceutical company sees great benefits from CIIE's spillover effect
STORY German pharmaceutical company sees great benefits from CIIE spillover effectSHOOTING TIME Recent footageDATELINE Nov 10 2024LENGTH 00011 ...
dvm36012d
Boehringer Ingelheim announces research and development facility expansion
The state-of-the-art research and development center in Georgia will help improve the health and wellbeing of animals ...